Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2017, Pages

  Shepherd, Andrew R H ^a,b   Shepherd, Emily ^c   Brook, Nicholas R ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; DRUG EFFICACY; HUMAN; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; CARCINOMA IN SITU; DISEASE COURSE; DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; META ANALYSIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT WITHDRAWAL; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA IN SITU; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-ALPHA; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; URINARY BLADDER NEOPLASMS; WITHHOLDING TREATMENT;

EID: 85014777880     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012112.pub2     Document Type: Review

References (80)

1. Bercovich E, Deriu M, Manferrari F, Irianni G. BCG vs BCG plus recombinant Alfa-Interferon 2b for superficial bladder TCC. Archivio Italiano Di Urologia e Andrologia 1995;67(4):257-60. 5302913
2. Irianni G, Ugolini G, Frigola M, Lo Cigno M, Emili E, Bertaccini A, et al. BCG Pasteur F and recombinant interferon alpha 2b in the prophylaxis of recurrent superficial neoplasia of the bladder: Preliminary results of a randomized study. Acta Urologica Italica 1993;7(Suppl 2):317-8. 5302914
3. Chiong E, Kesavan A, Mahendran R, Chan YH, Sng JH, Lim YK, et al. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder cancer. European Urology 2011;59(3):430-7. 5302916
4. Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007;109(6):1097-105. 5302917
5. Esuvaranathan K, Tham SM, Ravuru M, Kamaraj R, Ng TP, Chan YH, et al. Long term results of a double-blind randomised controlled trial of interferon alpha-2b and low dose BCG in patients with high risk non-muscle-invasive bladder cancer. BJU International 2014;113:1. 5302918
6. Esuvaranathan K, Tham SM, Ravuru M, Kamaraj R, Ng TP, Chan YH, et al. Long term results of a double-blind randomized controlled trial of interferon alpha-2b and low dose BCG in patients with high risk non-muscle-invasive bladder cancer. Journal of Urology 2014;1:e571. 5302919
7. Esuvaranathan K, Tham SM, Wu QH, Feng L, Lata R. BCG & interferon alpha: Defining its benefits & limitations in high risk non-muscle invasive urothelial carcinoma after long follow-up. International Journal of Urology 2010;17(Suppl 1):A52-3. 5302920
8. Gan YH, Mahendran R, James K, Lawrencia C, Esuvaranathan K. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer. Clinical Immunology 1999;90(2):230-7. 5302921
9. Sng JH, Lim YK, Wang ZT, Mani LRN, Chan YH, Win MTM, et al. Natural resistance-associated macrophage protein 1 (NRAMP1) gene polymorphisms and response to bacillus calmette-guerin therapy in Asian non-muscle invasive bladder cancer patients. Journal of Urology 2015;1:e381. 5302922
10. Vasdev N, Esuvaranathan K. Autoimmune clinical manifestations following intravesical bacillus calmette-guerin and interferon alpha 2b immunotherapy for superficial bladder cancer. Current Urology 2009;3(1):36-40. 5302923
11. Jarvinen R, Kaasinen E, Rintala E, Liukkonen T, Puolakka VM, Kallio J, et al. 15-year outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma (NMIBC) treated with 5 weekly mitomycin C (MMC) instillations followed by monthly Bacillus-Calmette Guerin (BCG) or alternating BCG and interferon-alpha2b (IFN) instillations. European Urology Supplement 2014;13(1):e1107. 5302925
12. Jarvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, Kallio J, et al. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly Bacillus Calmette-Guerin (BCG) or alternating BCG and interferon-alpha2b instillations: Prospective randomised finnbladder-4 study. European Urology 2015;68(4):611-7. 5302926
13. Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. European Urology 2002;42(2):167-74. 5302927
14. Kaasinen E, Rintala E, Pere A-K, Kallio J, Puolakka V-M, Liukkonen, et al. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. Journal of Urology 2000;164(1):47-52. 5302928
15. Minich AA. Combined intravesical immunotherapy for non-muscle invasive bladder cancer. Oncological Journal 2009;3(2):46-57. 5302931
16. Minich AA, Sukonko OG, Rolevich AI. Intravesical therapy with bacillus calmette-guerin plus interferon-α2B for non-muscle invasive bladder cancer. European Urology Supplement 2009;8(4):283. 5302930
17. Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL, Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. Journal of Urology 2010;184(5):1915-9. 5302933
18. Joudi FN, Smith BJ, O'Donnell MA, National BCG Interferon Phase Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urologic Oncology 2006;24(4):344-8. 5302935
19. O'Donnell MA, Lilli K, Leopold C, National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer [Erratum appears in J Urol. 2004 Dec;172 (6 Pt 1):2485]. Journal of Urology 2004;172(3):888-93. 5302937
20. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. European Urology 2017;71(3):447-61.
21. Bazarbashi S, Raja MA, El Sayed A, Ezzat A, Ibrahim E, Kattan S, et al. Prospective phase II trial of alternating intravesical Bacillus Calmette-Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results. Journal of Surgical Oncology 2000;74(3):181-4.
22. Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Science Translational Medicine 2012;4(137):137ra72. [DOI: 10.1126/scitranslmed.3003586]
23. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. European Urology 2002;41(5):523-31.
24. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. Journal of Urology 2011;186(6):2158-67.
25. Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. European Urology 2014;65(1):69-76.
26. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. International Journal of Cancer. Journal International du Cancer 2000;86(2):289-94.
27. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. European Urology 2013;63(2):234-41.
28. Cancer Research UK. Bladder cancer key facts. publications.cancerresearchuk.org/downloads/Product/CS_KF_BLADDER.pdf (accessed 30 December 2014).
29. Chou R, Buckley D, Fu R, Gore JL, Gustafson K, Griffin J, et al. Emerging approaches to diagnosis and treatment of non-muscle-invasive bladder cancer. Comparative Effectiveness Review No. 153. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ Publication No. 15(16)-EHC017-EF. Rockville, MD: Agency for Healthcare Research and Quality. October 2015. www.effectivehealthcare.ahrq.gov/reports/final.cfm (accessed 25 August 2016).
30. Chu H, Wang M, Zhang Z. Bladder cancer epidemiology and genetic susceptibility. Journal of Biomedical Research 2013;27(3):170-8.
31. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
32. Thomson Reuters. EndNote. Version X7.5.1. Thomson Reuters, 2016.
33. Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007;109(6):1097-105.
34. Esuvaranathan K, Tham SM, Wu QH, Feng L, Lata R. BCG & interferon alpha: Defining its benefits & limitations in high risk non-muscle invasive urothelial carcinoma after long follow-up. International Journal of Urology 2010;17(Suppl 1):A52-3.
35. Esuvaranathan K, Tham SM, Ravuru M, Kamaraj R, Ng TP, Chan YH, et al. Long term results of a double-blind randomised controlled trial of interferon alpha-2b and low dose BCG in patients with high risk non-muscle-invasive bladder cancer. BJU International 2014;113:1.
36. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. globocan.iarc.fr (accessed 1 January 2015).
37. Ferrantini M, Capone I, Belardelli F. Interferon-α and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007;89(6-7):884-93.
38. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306(7):737-45.
39. Gan YH, Mahendran R, James K, Lawrencia C, Esuvaranathan K. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer. Clinical Immunology 1999;90(2):230-7.
40. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Medicine 2011;8(5):e1001026.
41. McMaster University. GRADEpro GDT: GRADEpro Guideline Development Tool. Hamilton (ON): McMaster University, 2015 (developed by Evidence Prime Inc.). Available from www.gradepro.org.
42. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Schünemann HJ, et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.) 2008;336(7651):995-8.
43. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
44. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
45. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557-60.
46. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
47. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
48. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
49. Irianni G, Ugolini G, Frigola M, Lo Cigno M, Emili E, Bertaccini A, et al. BCG Pasteur F and recombinant interferon alpha 2b in the prophylaxis of recurrent superficial neoplasia of the bladder: Preliminary results of a randomized study. Acta Urologica Italica 1993;7(Suppl 2):317-8.
50. Joudi FN, Smith BJ, O'Donnell MA, National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urologic Oncology 2006;24(4):344-8.
51. Kaasinen E, Rintala E, Pere A-K, Kallio J, Puolakka V-M, Liukkonen, et al. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. Journal of Urology 2000;164(1):47-52.
52. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4-34.
53. Lam JS, Benson MC, O'Donnell MA, Sawczuk A, Gavazzi A, Wechsler MH, et al. Bacillus calmette-guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urologic Oncology 2003;21(5):354-60.
54. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100.
55. Loke YK, Golder SP, Vandenbroucke JP. Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources. Therapeutic Advances in Drug Safety 2011;2(2):59-68.
56. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. European Urology 2004;46(2):170-6.
57. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. Journal of Immunology (Baltimore, Md.: 1950) 1999;162(4):2399-405.
58. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. Journal of Urology 1976;116(2):180-3.
59. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-α 2b plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed. Journal of Urology 2001;166(4):1300-5.
60. Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. Journal of Urology 2001;166(6):2129-33.
61. Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World Journal of Urology 2009;27(3):289-93.
62. Punnen SP, Chin JL, Jewett MA. Management of bacillus Calmette-Guérin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Canadian Journal of Urology 2003;10(2):1790-5.
63. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
64. Rizza R, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-α: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010;43(3):204-9.
65. Schenkman E, Lamm DL. Superficial bladder cancer therapy. Scientific World Journal 2004;4(Suppl 1):387-99.
66. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
67. Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K, et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD006885.pub2]
68. Shelley M, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001986]
69. Shelley M, Court JB, Kynaston H, Wilt T, Coles B, Mason M. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD003231]
70. Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treatment Reviews 2010;36(3):195-205.
71. Shepherd ARH, Shepherd E, Brook NR. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Cochrane Database of Systematic Reviews 2016, Issue 3. [DOI: 10.1002/14651858.CD012112]
72. Sobin LH, Gospodariwicz M, Wittekind C (editors). TNM Classification of Malignant Tumors. UICC International Union Against Cancer. 7th Edition. Wiley-Blackwell, November 2009.
73. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. Journal of Urology 2004;171(6 Pt 1):2186-90.
74. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology 2006;49(3):466-77.
75. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. European Urology 2009;56(3):430-42.
76. Vasdev N, Esuvaranathan K. Autoimmune clinical manifestations following intravesical bacillus calmette-guerin and interferon alpha 2b immunotherapy for superficial bladder cancer. Current Urology 2009;3(1):36-40.
77. Vineis P, Simonato L. Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach. Archives of Environmental Health 1991;46(1):6-15.
78. Whelan P. The treatment of non-muscle-invasive bladder cancer with intravesical chemotherapy and immunotherapy. European Urology Supplements 2007;6(8):568-71.
79. Zhang Y, Khoo HE, Esuvaranathan K. Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. Journal of Urology 1999;161(3):977-83.
80. Zhu S, Tang Y, Li K, Shang Z, Jiang N, Nian X, et al. Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies. BMC Cancer 2013;13:332.